SCHEMBL6897289

SCHEMBL6897289

CCc1ccccc1N1CCN(C(=NO)Nc2cc(C)c(C)cc2OC)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.44
ALDH1A1 P00352 4/20 0.44
MEN1 O00255 3/20 0.44
TSHR P16473 3/20 0.44
RBP4 P02753 1/20 0.44
PKM P14618 1/20 0.43
NPSR1 Q6W5P4 3/20 0.43
LMNA P02545 2/20 0.43
MAPT P10636 2/20 0.42
RAB9A P51151 1/20 0.42
USP2 O75604 1/20 0.42
HTT P42858 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
HTR1A P08908 1/20 0.42
HTR1D P28221 1/20 0.42
HTR1B P28222 1/20 0.42
GAA P10253 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ATM Q13315 1/20 0.41
GFER P55789 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6780775 0.85 KMT2A (0.59) KMT2AALDH1A1MEN1PKMLMNA
SCHEMBL6897563 0.84 KMT2A (0.52) KMT2AALDH1A1MEN1TSHRRBP4
SCHEMBL6678798 0.81 KMT2A (0.39) KMT2AALDH1A1MEN1TSHRRBP4
SCHEMBL6898372 0.79 CYP3A4 (0.47) KMT2AALDH1A1MEN1RBP4PKM
SCHEMBL6899041 0.79 CYP3A4 (0.52) KMT2AALDH1A1MEN1RBP4NPSR1
SCHEMBL6896729 0.79 KMT2A (0.52) KMT2AALDH1A1MEN1TSHRRBP4
SCHEMBL6673633 0.79 PKM (0.46) KMT2AALDH1A1MEN1TSHRPKM
SCHEMBL6898814 0.78 CYP3A4 (0.42) KMT2AALDH1A1MEN1RBP4PKM
SCHEMBL6897989 0.77 KMT2A (0.41) KMT2AALDH1A1MEN1TSHRRBP4
SCHEMBL6677283 0.77 KMT2A (0.38) KMT2AALDH1A1TSHRRBP4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6683184-B2 ANTITUMOR AGENTS SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2004-01-27 US disclosed
US-20030092910-A1 Piperazine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2003-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092910-A1 Piperazine derivatives and process for the preparation thereof CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS KMT2A 2664/4885ALDH1A1 58/4885MEN1 3862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.